Amd Age-Related Macular Degeneration
Rapid Reviews in Retina™: Emerging Updates from Fall 2024 - Addressing the Wealth of New Data in Treatments for nAMD and DME
This activity is supported by an educational grant from Regeneron Pharmaceuticals.
Cases & Conversations™: Real World Review of Treat and Extend Strategies for Neovascular Retinal Disease
This activity is supported by Regeneron Pharmaceuticals, Inc.
Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.
Rapid Reviews in Retina™: Emerging Updates from Summer 2024 - Addressing the Wealth of New Data in Treatments for nAMD and DME
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.
Burst CME Plus<sup>™</sup> - Unveiling Pharmacological Advances in nAMD & DME: From Durability to Applicability
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.
Healio Minute Podcast, DME/Retina Edition: Top Headlines - Week of April 8, 2024
In this edition, PALADIN study navigates IOP-lowering surgery in DME patients, small-molecule eye drop well-tolerated as treatment for retinal vascular diseases and more.
Rapid Reviews in Retina™: Emerging Updates from Fall 2023 – Addressing the Wealth of New Data in Treatments for nAMD and DME
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.
Q&A: Stem cell patch aims to improve AMD vision loss
Easing the Burden of Retinal Diseases: A Focus on the Optimal Application of Intravitreal Therapy in DME and nAMD
Supported by an educational grant from Genentech, a member of the Roche Group.
Medical Crossfire<sup>®</sup>: Expert Insights in Anti-VEGF Dosing for nAMD and DME – Optimizing Reduction in Treatment Burden
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.